Free Newsletter
BBC: Reckitt schemed against generics
Reckitt Benckiser execs bragged in internal documents that they'd blocked generic competition for their Gaviscon stomach med for years--even after the drug went off patent. According to the BBC, The company blocked generic competition by citing health and patient safety, but documents show the execs were conspiring to throw up obstacles to the generics so they could preserve their Gaviscon revenue. In one document, an executive wrote, "Should we not drag it out as long as possible...nine million pounds of business is at stake."
One former exec told the network that Reckitt sold Gaviscon to the National Health Service for three times the cost of generics. The company had "cheated the NHS" and could have saved the state healthcare provider "millions of pounds," the former official said.
- read the BBC story
Related Article:
The specter of generic competition grows. Report
Analysts get bullish on generics makers. Report
Patent 'cliff' looms for Big Pharma. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





